A Comprehensive Approach to Optimizing Glycemic Control: Meaningful Engagement for Improved Patient Outcomes
Provided by Clinical Care Options, LLC in collaboration with the Endocrine Society, and RealCME

Acknowledgment
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Learning Objectives
Upon completion of this activity, learners should be able to:

• Describe the main components of CGM technology that can help patients to achieve and maintain tight glycemic control and guideline recommendations for their use
• Explore strategies to use CGM to optimize PPG and TIR control
• Explore strategies to use connected insulin pens with CGM to facilitate precise insulin dosing and tight glycemic control

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Steven V. Edelman, MD, has disclosed that he has served on medical advisory board and speaker’s bureaus for AstraZeneca, Lilly, MannKind, Merck, and Sanofi-Aventis and has served on medical advisory boards for BrightSight, Board Member: Senseonics, and TeamType1.

Vivian A. Fonseca, MD, FRCP, has disclosed that he has received consulting fees from Abbott, Asahi, AstraZeneca, Bayer, Intarcia, Novo Nordisk, Sanofi, and Takeda; has received funds for research support paid to his institution from Fractyl and Jaguar Gene Therapy; and has ownership interest in Amgen, Bravo, and Mellitus.

Irl B. Hirsch, MD, has disclosed that he has received funds for research support from Beta Bionics, Insulet, and Medtronic and consulting fees from Abbott, Bigfoot, GWave, and Roche.

Staff
CCO staff and planners have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience
This program is intended for healthcare professionals who treat patients with diabetes, including endocrinologists, internists, pharmacists, primary care physicians, pediatricians, obstetricians, advanced practice providers, and nurses

Goal
The goal of this CME/CE-certified curriculum is to establish impactful small group interactions between members of the diabetes care team that will, through a variety of collaborative educational experiences, help them to optimally use available therapeutics, new technology and shared decision-making to improve PPG management and TIR control, with a key focus of fully integrating CGM into daily practice.

Accreditation Information
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit
Physician Continuing Education
CCO designates this other activity, Gather-ed, for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this activity is 3.0 contact hours.

Program Medium
This program has been made available online.

Instructions for Credit
Participation in this activity should be completed in approximately 3.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 22 2021, through April 22, 2022:

1. Register online at https://clinicaloptions.gathered.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity.
4. To claim the maximum amount of credit available, you must complete all of the following:

• Completion of the Baseline and Final assessment Modules: 0.5 credit hours
• Completion of the Self Study Modules: 1 credit hour
• Participate in Live Group Discussion 1: 0.5 credit hours
• Participate in Live Group Discussion 2: 0.5 credit hours
• Completion of Group Task 1: 0.25 credit hours
• Completion of Group Task 2: 0.25 credit hours

Credit can be claimed upon the completion of the Post Group Assessment, which is issued when groups close.